Wikisage, the free encyclopedia of the second generation, is digital heritage
Belzutifan: Difference between revisions
Jump to navigation
Jump to search
(dutch wikiLink) |
No edit summary |
||
| Line 16: | Line 16: | ||
{{wikidata|Q27456641}} | {{wikidata|Q27456641}} | ||
{{refs}} | |||
[[nl:Belzutifan]] | [[nl:Belzutifan]] | ||
Revision as of 23:39, 13 August 2021
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]
ATC
none
|
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]
| References: |
|